Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance work on Wednesday 21st October 2020 from 07:00 AM to 07:00 PM (BST).

During this time our website performance may be temporarily affected. We apologise for any inconvenience this might cause and thank you for your patience.


All chapters
Previous chapter Next chapter

Chapter 3

Biological and Immunogenicity Evaluation Strategy for Therapeutic Peptides: Chemistry, Manufacturing and Controls Perspective

Assessment of the immunogenicity of peptides used for therapeutic purposes along with measurement of their biological activity is essential to evaluating the safety of therapeutic peptides. Accurate determination of the potency (biological activity) and evaluation of the immunogenicity of peptide-based therapeutic drugs for use in humans are crucial to their efficacy and safety. The assays used in determining the biological activity must closely follow the mechanism of action. A panel of assays can be used for testing the activity of a molecule. Several cell-based assay methods with a wide range of readouts can be used in the evaluation. These readouts can be cellular responses, signal transduction events, gene transcription reporter assays and/or ligand–receptor-binding cell-based assays using flow cytometry. Additionally, it is important to evaluate the immunogenic potential of the biologics in an appropriate fashion using a clearly defined strategy and clinical trials. The studies must include the appropriate risk assessment procedures and evaluation of immunogenicity using validated methods. The immune responses against the therapeutic biologics can be studied using various methodologies. These include enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR), chemiluminescence and flow cytometry assays for binding antibodies and cell-based assays for neutralizing antibodies. The immune responses to the biologics can vary widely in various cross-sections of the population, hence a combination of techniques is necessary to evaluate fully the immunogenic potential of the biologics. This chapter outlines various commonly used technology platforms and their merits and shortcomings.

Publication details


Print publication date
28 Aug 2019
Copyright year
2019
Print ISBN
978-1-78801-433-5
PDF eISBN
978-1-78801-644-5
ePub eISBN
978-1-78801-869-2
From the book series:
Drug Discovery